SPR

Sepiapterin reductase · P35270 · SPR on Sugi Atlas →

27,129 patent compounds predicted against SPR, 11,111 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1263823 SCHEMBL1263823 0.54 10/20
SCHEMBL1193113 SCHEMBL1193113 0.59 9/20
SCHEMBL1174425 SCHEMBL1174425 0.48 9/20
SCHEMBL309514 SCHEMBL309514 0.48 8/20
SCHEMBL942032 SCHEMBL942032 0.47 8/20
SCHEMBL308408 SCHEMBL308408 0.55 5/20
SCHEMBL829518 SCHEMBL829518 0.51 5/20
SCHEMBL3472 SCHEMBL3472 0.50 5/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL798115) 0.49 5/20
SCHEMBL333570 SCHEMBL333570 0.42 5/20
SCHEMBL574333 SCHEMBL574333 0.41 5/20
SCHEMBL1032085 SCHEMBL1032085 0.38 5/20
SCHEMBL824587 SCHEMBL824587 0.35 5/20
Acetylserotonin Acetylserotonin (SCHEMBL422165) 1.00 4/20
SCHEMBL1131640 SCHEMBL1131640 0.76 4/20
SCHEMBL1127784 SCHEMBL1127784 0.70 4/20
Oxalic Acid Oxalic Acid (SCHEMBL1320479) 0.70 4/20
SCHEMBL798165 SCHEMBL798165 0.70 4/20
SCHEMBL803617 SCHEMBL803617 0.69 4/20
SCHEMBL1132343 SCHEMBL1132343 0.69 4/20

Clinical trials — most relevant to SPR by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effects of Tetrahydrobiopterin (BH4) on Leg Blood Flow and Exercise Capacity in Patients With Peripheral Artery Disease PHASE4WITHDRAWN
Effects of Statin and Ezetimibe Association on Kinetics of Artificial Chilomicrons PHASE4COMPLETED
Clinical Role of Testosterone and Dihydrotestosterone and Which of Them Should be Inhibited in COVID-19 Patients - A Double-edged Sword? PHASE4UNKNOWN
The Role of Mineralocorticoid Receptors in Vascular Function PHASE2/PHASE3COMPLETED
A Study of PTC923 (CNSA-001) in Primary Tetrahydrobiopterin (BH4) Deficient Participants With Hyperphenylalaninemia PHASE1/PHASE2COMPLETED
Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis PHASE2UNKNOWN
Depletion of Serum Amyloid P Component to Enhance the Immune Response to DNA Vaccination PHASE1/PHASE2COMPLETED
Phase II Study of Simvastatin Plus Irinotecan, Fluorouracil, and Leucovorin(FOLFIRI) for Metastatic CRC PHASE2COMPLETED
Nitrite Infusion Studies PHASE1COMPLETED
The Effect of Antioxidants on Skin Blood Flow-BH4 PHASE1COMPLETED
Novel Approaches for Improving Vascular Function in Veterans With HFpEF PHASE1RECRUITING
Exercise and NO in HFrEF EARLY_PHASE1COMPLETED
Uterine Artery Doppler Changes After Vaginal Administration of Isosorbide Mononitrate In Patients With URPL EARLY_PHASE1UNKNOWN
Large-scale COVID-19 Population Screening nanUNKNOWN
European Survey: Risk of Cyanide Poisoning in Smoke Inhalation nanCOMPLETED
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients nanCOMPLETED
The Clinical Value of the Nitric Oxide System Components in Asthma and COPD nanUNKNOWN
Macrophage Migration Inhibitory Factor (MIF)- Cardiac Surgery nanCOMPLETED
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies nanENROLLING_BY_INVITATION
Gene-by-Smoking Interactions and Risk of Atherosclerosis - Ancillary to ARIC nanCOMPLETED
Rapid Test for Detection of the Focus of Infection in Post Neurosurgical Patients. nanUNKNOWN
Multi-center Controlled Clinical Trials in Alport Syndrome-A Feasibility Study nanCOMPLETED
Incidence of Iron Deficiency in Polycythemia Vera (PV) and Association With Disease Features nanUNKNOWN
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Efficacy and Safety of Angiotensin II Use in Coronavirus Disease(COVID)-19 Patients With Acute Respiratory Distress Syndrome nanUNKNOWN
Proof of Concept Creatine Supplementation for Homocystinuria Study nanACTIVE_NOT_RECRUITING
Genetic Variants and Regulation of Specialized Pro-resolving Mediator nanRECRUITING
External Nitric Oxide Measurement Through SNO Degradation nanENROLLING_BY_INVITATION
Epidemiology of Atherosclerosis nanCOMPLETED
Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a SPR binder may also engage these)

ProteinNameSimilarity
Q8R536 0.997 Q8R536 →
Q17QK8 0.996 Q17QK8 →
P18297 0.995 P18297 →
Q64105 0.992 Q64105 →
Q7ZY31 0.982 Q7ZY31 →
B0BML7 0.981 B0BML7 →
Q8R123 0.970 Q8R123 →
Q9HAB8 0.967 Q9HAB8 →
ABHD11 sn-1-specific diacylglycerol lipase ABHD11 0.965 landscape →
P51976 0.965 P51976 →
TARS2 Threonine--tRNA ligase, mitochondrial 0.964 landscape →
Q8K4F5 0.964 Q8K4F5 →
A0A1U8CC89 0.964 A0A1U8CC89 →
Q86TX2 0.964 Q86TX2 →
Q17QW3 0.963 Q17QW3 →
O57314 0.963 O57314 →
Q9HBH5 0.963 Q9HBH5 →
Q9ERI6 0.963 Q9ERI6 →
O77667 0.963 O77667 →
O95396 0.962 O95396 →
A0AAT9JA24 0.962 A0AAT9JA24 →
P51661 0.962 P51661 →
O43542 0.962 O43542 →
Q96LJ7 0.962 Q96LJ7 →
Q8WZ82 0.962 Q8WZ82 →
Q9BSH5 0.961 Q9BSH5 →
Q3SZ16 0.961 Q3SZ16 →
HSD17B1 17-beta-hydroxysteroid dehydrogenase type 1 0.961 landscape →
P85971 0.961 P85971 →
Q7T012 0.961 Q7T012 →